Neurowyzr, a Singapore-based healthtech company which specializes in brain health, raised additional US$2.1M in Seed funding.
The round, which brought the total amount to US$3.3M, was led by Jungle Ventures and Peak XV’s Surge, with participation from various angel investors including Khoo Boon Hui, Chairman of SDAX; Ab Gaur, Founder and CEO of MarTech firm Verticurl; and Rob F Jablonski, Commercial Investment Director, Aquivia Pty Ltd.
The company intends to use the funds to accelerate product development and embark on its next phase of regional expansion across Southeast Asia and India.
Established by Nav Vij and Pang Sze Yunn in 2019, Neurowyzr is a neuroscience and brain capital company which uses discoveries in neuroscience, advanced analytics and AI, to optimize corporate and population brain health and performance. Its first product is an online gamified digital neuroscience assessment called the Digital Brain Function Screen (DBFS), which reduces the time and costs of traditional cognitive testing.
Since launch, the team has worked to enable patient access to Digital Brain Function Screen (DBFS) across key markets. In Singapore, it can be found in a growing number of health screening centres, GP clinics, community care, and specialist centres, including Parkway Shenton, SATA Commhealth, Farrer Park Hospital, MHC Medical Centre (Amara), and O’Joy. The healthcare providers use DBFS in executive health screening, health screening for active agers, Long Covid assessment packages as well as a standalone service. One of India’s largest private hospital chains recently completed a pilot of the DBFS across five locations in India. DBFS has also been registered with the U.S. Food and Drug Administration.
FinSMEs
24/08/2023